Trinity Biotech’s Chief Technology Officer, Dr Gary Keating, added, “Our next phase of refinements, guided by this study’s positive results, will be tested in a second European pre-pivotal trial, ...
Senseonics' Eversense 365 is approved in the US as an integrated continuous glucosemonitoring (iCGM) system for people with Type 1 and Type 2 diabetes aged 18 and older Commercial launch by ...
Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for ...